ER+/HER2- EARLY BREAST CANCER
Clinical trials for ER+/HER2- EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER+/HER2- EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for ER+/HER2- EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to keep breast cancer from coming back
Disease control Recruiting nowThis Phase 3 trial is testing a new daily pill called camizestrant against standard hormone therapies (like tamoxifen or aromatase inhibitors) in 5,500 people with ER+/HER2- early breast cancer who have a moderate-to-high risk of the cancer returning. Participants take the drug f…
Matched conditions: ER+/HER2- EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New daily pill could keep breast cancer from coming back
Disease control Recruiting nowThis study tests a new daily pill, camizestrant, against standard hormone therapies to see if it better prevents breast cancer from returning in people with ER+/HER2- early breast cancer who are at intermediate or high risk. About 4,300 participants who have already completed ini…
Matched conditions: ER+/HER2- EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC